Cardiologists, Endocrinologists and GPs

All content regarding the disease or patient opinion had to be medically accurate and fully substantiated.

Treatment and control of dyslipidaemia is needed to reduce or prevent the risk of cardiovascular (CV) disease. Statins reduce CV risk but type 2 diabetes (T2D) patients with increased triglycerides (TGs) and low HDL-C still have a substantial residual risk. Lipanthyl, a fenofibrate, is used to lower triglycerides and lower CV risk. Research suggests that both a statin and a fenofibrate are necessary for adequate CV protection in these patients.